BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

Small-cell lung cancer (SCLC) is the most aggressive type of lung cancer. Each year in the U.S., about 30,000 to 35,000 people are diagnosed with it. For most, it has already spread to distant ...

Positive preliminary data from the phase 1b/2 trial evaluating Olvi-Vec in small cell lung cancer have been announced.

Doctors stage non-small cell lung cancer (NSCLC) according to how far it has progressed. Stages range from occult (or hidden) cancer to stage 4 cancer, in which multiple organs may be affected.

Lung cancer is a disease in which cancerous cells form in the tissues around and inside the lung. There are various types of this disease. Non-small cell lung cancer (NSCLC) is a disease where cancer ...

The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...

Candel Therapeutics has identified a subpopulation of lung cancer patients living longest on its oncolytic virus, leading the biotech to narrow its focus as it heads towards a potentially ...

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All ...

FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population ...

Stages of Non-Small Cell Lung Cancer Once a person has been diagnosed with cancer, their healthcare team conducts additional tests to determine the cancer stage. The stage describes how advanced ...